No fewer than 20 companies are working on next-generation lipid-lowering agents intended to improve upon the benefits of statins, which lower LDL-C and reduce the risk of cardiovascular events but still leave millions of people above target LDL-C levels. While most are developing their compounds in similar settings - generally as add-ons to high-dose statins in patients not achieving LDL-C goals - emerging data suggest different mechanisms may turn out to be appropriate for different populations.

In March two mAbs that inhibit proprotein convertase subtilisin/kexin 9 made headlines with new clinical data.